FDA advisers reject Primatene OTC inhaler

26 February 2014 - Deborah Wilkes

Archived

Armstrong Pharmaceuticals has run into trouble with its plan to get an OTC asthma inhaler back on the market in the US under the established Primatene brand name.

Click tags below for more information on topics:

FDA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: